ESTIMATION OF HMG-COA REDUCTASE INHIBITOR HAS CHRONOPHARMACEUTICAL DELIVERY SYSTEM VIA NOVEL COATING METHODAbstract
Introduction: The aim of the present study is to formulate and evaluate the simvastatin chronopharmaceutical delivery system using a novel coating method to mimic the circadian rhythm of the disease by releasing the drug with a distinct predetermined lag time of 6 h. Observation: Simvastatin is a hyperlipidemia drug that inhibit the synthesis of cholesterol by inhibiting the HMG-COA reductase enzyme. Experiment: The basic design of the system consists of a rapid release core and a controlled release coat. The powder blend was evaluated for the angle of repose, Carr’s index, Hausner ratio, and compressibility index. The core tablet was evaluated for in-vitro release. The coated tablet was evaluated for weight variation, hardness, thickness, friability, disintegration, in-vitro dissolution, in-vitro comparative study, acid uptake test, rupture test, swelling studies, SEM, stability studies and FTIR, etc. Results and Discussion: The preformulation studies were revealed compatible results, and the rupture time, swelling time, acid uptake study showed satisfactory results by which it indicates the core molecule will be released at a prominent time period so that the availability of the drug entity has been greater base on the chronological behavior of the disease. In this study among the seven formulations, the formulations F7 shows a better drug release of 98.8% at the end of 10 h. Conclusion: From the above results, it concluded the release of drugs was based on disease condition, so the release and bioavailability of a drug entity will be better and constant throughout the disease condition in order to increase the level of therapy.